Cancer company BeiGene Co. Ltd. was founded in Beijing in 2010 in part to access China's large and growing pool of scientific talent. When it came time to build an SAB with clinical development expertise, however, the biotech needed to recruit several members from the U.S.

"We wanted an SAB with clinical experience both from the industry side and from the clinician side," co-founder and CEO John Oyler told BioCentury. "There is not deep expertise in how you go through the Phase I/II process, what the dosing regimen should be and how you approach it. If you want to access that knowledge, it doesn't exist in China."